Pfizer (NYSE:PFE) has been given a $42.00 price objective by Royal Bank of Canada in a research note issued to investors on Tuesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 14.07% from the stock’s previous close. PFE has been the topic of...
Read Full StoryRelated
, 5min
0
, 5min
0
, 8min
0
, 9min
0
, 13min
0